Drug Approval Standards
Vinay argues for a higher bar in drug approval, suggesting that merely shrinking tumors is insufficient if it doesn't lead to improved survival. He highlights the flaws in the current system, where taxpayer money funds potentially harmful drugs. Russ adds that the U.S. bears the brunt of drug innovation costs, with other countries benefiting from lower prices, raising questions about accountability and fairness in drug pricing.In this clip
From this podcast
EconTalk
Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
Related Questions